蛋白酶體抑制劑市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球蛋白酶體抑制劑市場價值為 27 億美元，預計 2025 年至 2034 年的複合年成長率為 8.7%。蛋白酶體抑制劑是一類細胞毒性藥物，可阻斷蛋白酶體的糜蛋白酶樣酶活性，破壞細胞內的蛋白質分解，並表現出強大的抗癌潛力。目前，這些抑制劑主要用於腫瘤學治療多發性骨髓瘤和套細胞淋巴瘤等疾病。正在進行的臨床試驗旨在擴大其臨床應用範圍。製藥公司正在加大研發投入，推出療效更高、臨床適應症更廣泛、合併治療相容性更好的新型蛋白酶體抑制劑。人們越來越關注提高治療效果和解決抗藥性問題，這推動著該市場的創新。

市場依藥品類型分為品牌藥品和學名藥。受針對性療法治療多發性骨髓瘤的日益普及的推動，品牌蛋白酶體抑制劑在 2024 年佔據了總市場佔有率的 64.8%。全球多發性骨髓瘤發生率的上升推動了對具有療效證明和優良患者治療效果的品牌藥物的需求。品牌療法表現出更高的標靶親和力，能夠有效抑制蛋白酶體活性並更好地控制疾病。聯合療法的使用日益增多，例如將蛋白酶體抑制劑與免疫調節劑和皮質類固醇結合，進一步加速了該領域的成長。

根據應用，蛋白酶體抑制劑市場分為多發性骨髓瘤和套細胞淋巴瘤。 2024 年，多發性骨髓瘤治療佔了 92.5% 的市場佔有率，這主要是由於新診斷病例數量的增加以及對早期發現和治療的認知的提高。多發性骨髓瘤的盛行率不斷上升，促使患者和醫療保健提供者尋求更有針對性的治療方案，其中包括蛋白酶體抑制劑。隨著創新療法的普及和診斷技術的進步，適合接受蛋白酶體抑制劑治療的患者群體顯著擴大。

配銷通路細分包括醫院藥局、零售藥局、電子商務。 2024 年，醫院藥局的收入將達到 19 億美元，佔據分銷市場的主導地位。蛋白酶體抑制劑通常透過皮下或靜脈注射給藥，需要在醫院環境中接受專門護理。醫院擁有管理複雜療法和監測潛在副作用的良好設備，這鼓勵醫院藥房更多地購買這些藥物。此外，主要保險公司為醫院購買提供更優惠的報銷率，進一步加強了該領域的主導地位。

在北美，美國蛋白酶體抑制劑市場預計將大幅成長，從 2024 年的 11 億美元增加到 2034 年的 25 億美元。多發性骨髓瘤的高發生率以及篩檢和診斷技術的進步正在推動市場成長。專注於開發新型蛋白酶體抑制劑的領先生物技術和製藥公司的存在為區域市場擴張做出了重大貢獻。隨著研究工作不斷開闢新的治療應用，市場將在預測期內實現強勁成長。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 多發性骨髓瘤及相關癌症的盛行率不斷上升
    • 藥物開發和核准的進展
    • 腫瘤學研究投資不斷增加
    • 新興市場的擴張
  • 產業陷阱與挑戰
    • 治療費用高
    • 不良副作用和抗藥性
• 成長潛力分析
• 監管格局
• 差距分析
• 專利分析
• 管道分析
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按藥物類型，2021 年至 2034 年

• 主要趨勢
• 品牌
  • Velcade（硼替佐米）
  • Kyprolis（卡非佐米）
  • 尼拉羅（伊沙佐米）
• 通用的

第6章：市場估計與預測：按應用，2021 年至 2034 年

• 主要趨勢
• 多發骨髓瘤
• 套細胞淋巴瘤

第7章：市場估計與預測：按配銷通路，2021 年至 2034 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 電子商務

第8章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• Amgen
• Apotex
• Aurobindo Pharma
• Baxter International
• Bristol Myers Squibb
• Camber Pharmaceuticals
• Dr. Reddy's Laboratories
• Eugia US
• Fresenius Kabi
• Gland Pharma
• Johnson & Johnson
• QLi5 Therapeutics
• Sagent Pharmaceuticals
• Selleck Chemicals
• Takeda Pharmaceutical Company
• Zydus

The Global Proteasome Inhibitors Market was valued at USD 2.7 billion in 2024 and is projected to expand at a CAGR of 8.7% from 2025 to 2034. Proteasome inhibitors, a class of cytotoxic medications, block the chymotrypsin-like enzymatic activity of the proteasome, disrupting protein degradation within cells and exhibiting strong anticancer potential. Currently, these inhibitors are primarily used in oncology to treat conditions such as multiple myeloma and mantle cell lymphoma. Ongoing clinical trials aim to broaden the scope of their clinical applications. Pharmaceutical companies are increasing investments in research and development to introduce new proteasome inhibitors with higher efficacy, broader clinical indications, and improved compatibility for combination therapies. The growing focus on enhancing treatment outcomes and addressing drug resistance is driving innovation in this market.

The market is segmented by drug type into branded and generic categories. Branded proteasome inhibitors accounted for 64.8% of the total market share in 2024, driven by the rising adoption of targeted therapies to manage multiple myeloma. Increased incidence of multiple myeloma globally is boosting demand for branded medications with proven efficacy and superior patient outcomes. Branded therapies exhibit higher target affinity, enabling effective inhibition of proteasome activity and better disease control. The growing use of combination therapies, such as combining proteasome inhibitors with immunomodulatory agents and corticosteroids, is further accelerating segment growth.

By application, the proteasome inhibitors market is divided into multiple myeloma and mantle cell lymphoma. Multiple myeloma therapies accounted for 92.5% of the market share in 2024, primarily due to a rising number of newly diagnosed cases and increased awareness about early detection and treatment. The growing prevalence of multiple myeloma is prompting patients and healthcare providers to seek more targeted treatment options, which include proteasome inhibitors. Increased access to innovative therapies and improved diagnostic technologies has significantly expanded the patient pool eligible for treatment with proteasome inhibitors.

The distribution channel segmentation includes hospital pharmacies, retail pharmacies, and e-commerce. Hospital pharmacies generated USD 1.9 billion in revenue in 2024, dominating the distribution landscape. Proteasome inhibitors are typically administered via subcutaneous or intravenous routes, requiring specialized care in hospital settings. Hospitals are well-equipped to manage complex therapies and monitor potential side effects, which encourages higher procurement of these medications from hospital pharmacies. Additionally, major insurance providers offer more favorable reimbursement rates for hospital-based purchases, further strengthening the dominance of this segment.

In North America, the US proteasome inhibitors market is expected to grow substantially, increasing from USD 1.1 billion in 2024 to USD 2.5 billion by 2034. High incidence rates of multiple myeloma, along with advancements in screening and diagnostic technologies, are driving market growth. The presence of leading biotechnology and pharmaceutical companies focused on developing novel proteasome inhibitors is contributing significantly to regional market expansion. As research efforts continue to unlock new therapeutic applications, the market is set to witness strong growth through the forecast period.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of multiple myeloma and related cancers
    • 3.2.1.2 Advancements in drug development and approvals
    • 3.2.1.3 Growing investments in oncology research
    • 3.2.1.4 Expansion in emerging markets
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High treatment costs
    • 3.2.2.2 Adverse side effects and drug resistance
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Gap analysis
• 3.6 Patent analysis
• 3.7 Pipeline analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Branded
  • 5.2.1 Velcade (bortezomib)
  • 5.2.2 Kyprolis (carfilzomib)
  • 5.2.3 Ninlaro (Ixazomib)
• 5.3 Generic

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Multiple myeloma
• 6.3 Mantle cell lymphoma

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Amgen
• 9.2 Apotex
• 9.3 Aurobindo Pharma
• 9.4 Baxter International
• 9.5 Bristol Myers Squibb
• 9.6 Camber Pharmaceuticals
• 9.7 Dr. Reddy's Laboratories
• 9.8 Eugia US
• 9.9 Fresenius Kabi
• 9.10 Gland Pharma
• 9.11 Johnson & Johnson
• 9.12 QLi5 Therapeutics
• 9.13 Sagent Pharmaceuticals
• 9.14 Selleck Chemicals
• 9.15 Takeda Pharmaceutical Company
• 9.16 Zydus